Molecular typing and differentiation of Mycobacterium tuberculosis clinical isolates using Double Repetitive Element PCR and Duplex PCR  by Maruthai, Kathirvel et al.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 6 0 –6 6
.sc iencedi rect .comHO ST E D  BY Avai lab le at wwwScienceDirect
journal homepage: www.elsev ier .com/ locate / IJMYCOMolecular typing and differentiation
of Mycobacterium tuberculosis clinical isolates
using Double Repetitive Element PCR and
Duplex PCRhttp://dx.doi.org/10.1016/j.ijmyco.2014.11.061
2212-5531/ 2015 Asian African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Tel.: +91 0413 2272241; fax: +91 0413 2336262.
E-mail addresses: katkin14@gmail.com (K. Maruthai), thirumuruganphd@gmail.com (T. Ravibalan), k.vallayyachari@
(K. Vallayyachari), surenmicro39@gmail.com (S. Kesavan), antonysamrot@gmail.com (A.V. Samrot), stdcirlpdy@gmail.com (M. M
Peer review under responsibility of Asian African Society for Mycobacteriology.Kathirvel Maruthai a, Thirumurugan Ravibalan a,b, Kommoju Vallayyachari a,
Surendar Kesavan a, Antony V. Samrot b, Muthuraj Muthaiah a,*
a Department of Microbiology, Intermediate Reference Laboratory, Government Hospital for Chest Diseases, Gorimedu, Puducherry 605006,
India
b Department of Biotechnology, Sathyabama University, Chennai 600119, Tamilnadu, IndiaA R T I C L E I N F O A B S T R A C TArticle history:
Received 28 October 2014
Accepted 2 November 2014
Available online 13 January 2015
Keywords:
Mycobacterium tuberculosis
Double Repetitive Element PCR
Duplex PCR
Nontuberculous mycobacteria
Drug resistant tuberculosis
GenotypingBackground: To date, the advancements in polymerase chain reaction (PCR) assures
accurate, fast identification and mycobacterial speciation in clinical settings, which
promotes a better tuberculosis (TB) treatment regimen.
Methods: In this study, a total of 78 clinically suspected cases of TB were processed for the
detection of Mycobacterial infections by standard Ziehl Neelsen (ZN) staining, conventional
Lowenstein–Jensen (LJ) and BACTEC MGIT-960TM liquid culture. Strain typing was performed
by using Double Repetitive Element PCR (DRE-PCR) and Duplex PCR (DPCR) to differentiate
Mycobacterium tuberculosis complex (MTB) from non-tuberculous mycobacteria (NTM),
respectively.
Results: Of 78 clinical isolates, 25 (32%) were drug-susceptible, and 53 (68%) were resistant
to at least one drug. The BACTEC MGIT-960TM showed the highest (88.5%) positivity rate,
compared with conventional LJ (82%) and ZN smear (61.5%). The mean time detection
and drug susceptibility for MTB was 28 and 40 days in LJ culture, and 10 and 13 days in
BACTEC MGIT-960TM culture. Using DPCR, Mycobacterium avium infection was identified in
HIV-positive (2.56%) and MTB in HIV-negative patients (97.4%), and the DRE-PCR system
divulged 15 unique genotype patterns, and an institutional-based epidemiology database
was created.
Conclusions: The combination of an in-house DRE–DPCR system could possibly identify and
differentiate MTB from other mycobacterial species in a single reaction. In addition,
restriction polymorphism analysis and DNA sequencing of NTM could assist in species
identification directly from clinical isolates.
 2015 Asian African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.gmail.com
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Tuberculosis (TB) remains a global pandemic and kills mil-
lions of people worldwide even though effective treatment
is available [1]. Approximately 40% of the world’s TB cases
are from India and China [1] (WHO 2012). The increased prev-
alence and mortality of TB made an urgent call to enhance
rapid diagnosis, as delayed diagnosis of mycobacterial
infections leads to late and improper anti-TB treatment;
differentiation of mycobacteria is also essential to facilitate
epidemiology [2,3]. Up til now, conventional procedures like
X-ray filming, Ziehl Neelsen (ZN) sputum microscopy and
solid culturing on Lowenstein–Jensen (LJ) for TB diagnosis is
being followed in developing countries, all of which fail to
differentiate mycobacterial species in clinical specimens.
The problem associated with LJ culturing is that it takes
months to carry out drug sensitivity testing (DST). Most
importantly, the success rate depends on an experienced
person’s investigation [4–7].
Advancements in molecular biology like various polymer-
ase chain reaction (PCR) procedures and automated liquid
culture detection systems allow for rapid identification and
speciation of mycobacteria alongside the clinical specimen
with significant sensitivity than conventional procedures
[4,8,9]. Regardless of the false positivity (i.e., detection of dead
bacilli in the specimen) of the PCR application in TB diagnosis,
it allows for a timely and accurate identification of mycobac-
teria in a variety of clinical specimens, but it fails to meet
the requirement of precise speciation of Mycobacterium
tuberculosis complex (MTB) infection from non-tubercular
mycobacteria [7,9,10] in certain circumstances. It is important
to identify and differentiate the causative mycobacteria and
non-tuberculous mycobacterium (NTM) infection, as NTM
can cause problems in clinical settings, as its pathogenic
potential varies in susceptibility tests towards anti-tuberculo-
sis drugs [11]. A simplified multiplex PCR assay was developed
to differentiate MTB from NTM based on the specific nucleo-
tide variation in the RNA polymerase b-subunit encoding
gene (rpoB) [12].
Therefore, in this study, a combination of PCR procedures
was adapted using specific gene targets viz DRE-PCR (amplifi-
cation of DNA segments located between two repetitive
elements IS6110 and the polymorphic GC-rich repetitive
sequence [PGRS]) and Duplex PCR (DPCR) (amplify the rpoB
DNAs of MTB and NTM) from clinical specimens. The DPCR
products were further digested with MspI enzyme and
subjected to DNA sequencing. On the whole, PCR results were
evaluated with the results of ZN sputum smear microscopy, LJ
culture and BACTEC MGIT-960TM culture systems.
Materials and methods
Study settings
A panel of 78 MTB clinical isolates were obtained from TB
patients. Patients with clinical symptoms suspected for TB
infection were enrolled in this study and hospitalized on the
physician’s advice for TB diagnosis, and hospitalized treat-
ment-failure TB patients’ samples were also analyzed. Theclinical specimens were obtained for diagnosis as per the
routine laboratory investigation.
Sample processing procedure
Fig. S1 illustrates the detailed sample testing procedure that
was followed for the diagnosis to identify and to differentiate
MTB complex from NTM species from the clinical specimen.
For culture, clinical specimens were processed with NaOH–
NALC and were inoculated onto LJ culture slants. All inocu-
lated culture tubes were incubated at 37 C and contamina-
tion was checked daily for the first week and was observed
for colony formation once in every week for 8 weeks
[7,13,14]. For BACTEC MGIT-960TM culture, cerebrospinal fluid
(CSF), lymph node tissue extract, endometrial tissue extract
and pleural fluid were directly inoculated into MGIT-960 tubes
and remaining sampleswere carried out for DNA isolation. All
samples were confirmed for acid fast bacilli (AFB) by ZN stain-
ing and further subjected for identification of MTB complex
using p-nitro benzoic acid (PNB) assay [15].
Identification of mycobacteria
Originally, identification of mycobacteria at the species level
was done based on colony morphology, pigmentation profile,
and growth rate on conventional solid media. In addition, the
biochemical test results were performed, such as niacin test,
nitrate reductase test and heat-stable catalase test (pH 7.0,
68 C). Identification procedures attempted only to differenti-
ate MTB and NTM infection from clinical specimens to aid
results with DRE-PCR and DPCR procedures.
In vitro phenotypic drug susceptibility testing
Conventional LJ [13] and BACTEC MGIT 960TM [14] were used to
determine the drug susceptibility profile of the clinical iso-
lates against first-line anti-tuberculosis drugs. The standard
reference strain MTB H37Rv ATCC 27294 was used as the
DST control.
Mycobacterial genomic DNA isolation
Phenol: Chloroform extraction method was used to extract
genomic DNA directly from the clinical specimen, as well as
from well-grown cultures of both drug resistant and drug
susceptible as described previously [16]. DNA samples were
stored at 20 C for further PCR analysis.
PCR amplification
The complete list of primers used in this study is summarized
in Table S1. Identification of mycobacterium at the species
level was done by in-house PCR amplification of IS6110 ele-
ment directly from clinical specimens and grown cultures
with primers IS1 and IS2 as described previously [17]. Strains
with no IS6110 element were further amplified with mtp40
gene primers PT3 and PT5 as described previously [17]. The
DRE-PCR was performed as described previously [18]. Briefly,
the DRE-PCR step was performed in a final volume of 50 ll.
Each reaction tube contained 15 ll of 5· PCR Master mix
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Tris–HCl (pH 8.6), 25 units/ml Taq DNA polymerase, 50 mM
KCl, 5% glycerol, 0.2 mM each of dNTPs, final buffer 1·,
1.5 mM MgCl2, 0.08% IGEPAL
 CA-630, 0.05% Tween 20 and
10 pmol of each primers: Ris 1, Ris 2, Pntb 1, Pntb 2 per ll.
To increase the intensity of bands and the discrimination
power of DRE-PCR technique, the amount of template DNA
(2–5 ll) and Taq polymerase (1–1.5 U) were increased in an
extension step to 2 min instead of the usual 1 min extension.
Differential identification of MTB isolates
Amplification of rpoB gene-specific nucleotide variation by
DPCR was performed to distinguish MTB from NTM isolates
as described previously [12]. Essentially, the DPCR step was
performed in a final volume of 50 ll. Each reaction tube
contained 15 ll of 5· PCR Master mix solution (New England
Biolabs, USA) that contained 10 mM Tris–HCl (pH 8.6),
25 units/ml Taq DNA polymerase, 50 mM KCl, 5% glycerol,
0.2 mM each of dNTPs, final buffer 1·, 1.5 mM MgCl2, 0.08%
IGEPAL CA-630, 0.05% Tween 20 and 10 pmol of each pri-
mer: Tbc1, Tbc2 and M5, RM3 per ll and 2 ll of template
DNA were added finally. PCR was performed with an initial
denaturation of 95 C for 5 min, 30 cycles of amplification
(30 s at 95 C, 60 s at 72 C) and a final elongation at 72 C for
5 min. A Master Cycler Gradient PCR system 5331H52314
(Eppendorf) was used for all amplification reactions.
Restriction digestion analysis of NTM strains
Restriction enzyme MspI was selected based on the rpoB gene
sequence and directly applied to the PCR products of the
suspected specimen. Ten micro liters of PCR amplified prod-
ucts of NTM isolate; 1–2 U of restriction enzyme (New England
Biolabs); and restriction buffer 4TM were added to the 0.5 ml
fresh micro centrifuge tube and finally nuclease free water
was added to a final volume of 25 ll reaction. Restriction
digestion was performed at 37 C for 1–2 h in a controlled heat
environment (Thermal cycler) and was electrophoresed in 2%
agarose gel. The suspected NTM isolate’s digested DNA
products were subjected to automated DNA sequencing with
primers M5 and RM3 separately as previously described [12].
Agarose gel electrophoresis
DRE-PCR, DPCR amplified and restriction digested products
were resolved on 2% agarose gel with 100-bp DNA ladder
(HiMedia, India). DNA fingerprints were analyzed visually,
and the position and pattern similarity were observed and
used for the strain differentiation. Variations in band inten-
sity were not taken to constitute strain differences.Results
A total of 78 patients, 64 (82%) males and 14 (18%) females
were included in this study. Of these, 76 (97.4%) were HIV-neg-
ative and 2 (2.6%) were HIV-positive, who were male patients
aged 47 and 38 also included in the study. The common
clinical manifestations in these patients were weight loss,fever, and severe cough. Of the 78 clinically suspected
patients, 61 (78.2%) patients had pulmonary TB infection
and 17 (21.8%) had extrapulmonary TB (ETB) (5 CSF, 3 lymph
node tissue, 5 blood, 3 endometrial tissue and 1 pleural fluid).
The isolation and drug susceptibility profile of mycobacte-
ria from clinical specimens were studied and summarized in
Tables 1 and 2. The primary culture recovery mean time
detection and drug susceptibility for MTB was 28 and 40 days
in solid LJ culture and 10 and 13 days in BACTEC MGIT-960TM
culture. The total positivity for BACTEC MGIT-960TM was
88.4%, LJ was 82% and ZN smear had 61.5% (Table 1). The
low positivity rate obtained in ZN smear and LJ was due to
low bacilli loads in the clinical specimen. Table 2 summarizes
the drug susceptibility results obtained from conventional LJ
and BACTEC MGIT-960TM methods.
Both phenotypic and genotypic procedures were followed
for differential identification of MTB and NTM from clinical
specimens in this study setting. Conventional biochemical
assays viz. PBN test, niacin production, nitrate reductase
and catalase-peroxidase tests, along with various PCR proce-
dures viz. IS6110, mtp40 were performed, and tests results
were summarized in Table 3. An NTM strain Mycobacterium
avium was identified from 2 (2.56%) HIV-positive patients by
biochemical assays, and the results were confirmed with
DPCR and DNA sequencing methods.
In total, 15 different DRE-PCR patterns were obtained and
separated into 6 categories based on the number of bands,
position and their similarity (Figs. 1 and 2a–c). Category I
(10.3%) was comprised of 8 strains with 5 bands (Fig. 1c lanes
2 and 3). Category II (18%) was comprised of 14 strains with 4
bands (Fig. 1c lane 4). Category III (46.2%) was observed in 36
strains with 3 bands (Fig. 1b, lanes 1–6). Category IV (16.6%)
contained 13 strains with 2 bands (Fig. 1a, lanes 6, 10, 11, 16
and 18). Category V contained 5 strains (6.4%) with 1 band
(Fig. 1a lane 2), and Category VI (2.5%) contained 2 strains with
no band (Fig. 1a, lanes 7, 17 and 19).
Bands were obtained with amplification of genome posi-
tion in MTB, and their pattern was observed and analyzed
in agarose gel (examples shown in Fig. 1 DRE-PCR assay).
Twenty-five MDR and 14 RIF mono-resistant strains were
observed with 4 bands, in which the majority of the strains
demonstrated a similar banding pattern. Among them, 22
strains demonstrated the same banding pattern, 15 strains
constituted another category and the remaining strains
showed a difference in position of a single or more of ampli-
cons (Fig. 1b and c). One strain showed 1 band after two times
of PCR amplification; 20 strains (80%) among the 25 suscepti-
ble strains showed 5 bands completely different from the
others (Fig. 1c). To evaluate the clinical applicability of the
DRE-PCR, samples were subjected to two rounds of amplifica-
tion reactions, and most of the strains demonstrated the
same profile, and the position of the stronger bands were
identical; therefore, they were designated as signature bands
(Fig. 1a).
The diversification of MTB complex strains from NTM was
confirmed further by DPCR assay. A clear band at 235-bp
amplicon (Fig. 2) in agarose gel depicted the presence of
MTB strains, and the band at 136-bp amplicon (Fig. 3) in
agarose gel indicates the presence of M. avium strain, an
NTM obtained from HIV-positive patients. After amplification
Table 1 – Rates of recovery of mycobacteria and relationship of concentrated specimen microscopy with mycobacterial culture
on individual system/medium.
Culture system/Media ZN smear microscopy Total
Smear positive Smear negative Smear negative Smear positive
Culture positive Culture positive Culture negative Culture negative
MGIT-960TM 48 (61.5%) 21 (26.9%) 0 9 (11.5%) 78
L–J 45 (57.7%) 19 (24.3%) 2 (2.6%) 12 (15.4%) 78
Table 2 – Drug resistance profile of M. tuberculosis clinical
isolates.
Drugs No. of isolates
H + E + R + S 9 (11.5%)
H + E + R 2 (2.6%)
H + R 16 (20.5%)
R + E 2 (2.6%)
R 14 (17.9%)
H 10 (12.8%)
Susceptible 25 (32.1%)
Total 78 (100%)
H: Isoniazid; S: Streptomycin; E: Ethambutol; R: Rifampicin.
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DNA amplicon in agarose gel was further analyzed by restric-
tion fragment length polymorphism (RFLP) and by direct
sequencing for species identification (IIT, Chennai, India).
Discussion
In clinical settings, it is difficult to identify and differentiate
the infection caused by MTB and NTM by conventional proce-
dures because of the similar clinical manifestations. Thus, it
delays making a definitive diagnosis, and negatively impairs
TB treatment [3,19]. To date, several PCR-based procedures
are available for rapid identification and differentiation of
MTB, but high priority is recommended to identify mycobac-
terial infections at the species level [20]. In this preliminary
study, the prevalence of strain type among this setting was
studied and found that drug-resistant strains were predomi-
nant in this clinical setting [21]. Hence, this study is extended
to identify and differentiate the speciation of mycobacterial
infection with reference to the prevalence of drug-resistant
strains among the hospitalized patients. In addition, 19
MDR-TB (24.3%) hospitalized treatment-failure patients were
included in this study setting.Table 3 – Detection of mycobacterial infections by conventional
Organism/Species PNB
test
Niacin
test
Nitrate
reductase
test
Mycobacterium tuberculosis S +ve +ve
Mycobacterium avium R ve ve
S: Susceptible; R: Resistant; PNB: p-nitro benzoic acid; PCR: Polymerase cAmong the 78 isolates studied, the majority of the strains
(46.1%) were identified as Genotype C (Category III), which
was observed with 3 bands, and shared a common banding
pattern [18,21]. Category III consists of 7 strains from 4
drug-resistant isolates, 13 strains from MDR-TB, and 9 from
INH-resistant isolates. The majority of the strains in Category
III/drug-resistant demonstrated similar epidemiology pat-
terns and similar banding patterns (Fig. 1b). Interestingly,
clinical strains with drug susceptibility showed a maximum
number of bands (5 bands) than other counterparts (Fig. 1c).
A different DRE-PCR pattern was obtained from epidemiolog-
ically unrelated MTB strains from patients, whereas the same
DRE-PCR pattern was observed with epidemiologically related
MTB strains from patients.
In recent years, there has been an increase in the inci-
dence of TB cases due to mycobacteria other than MTB com-
plex (MOTT) reported in clinical settings. This is important in
the clinical treatment view, especially in terms of treatment
strategies and rapid differentiation of causative organisms
[8,12,22]. In this study, identification and differentiation of
MTB and NTM was performed by the PCR amplification of
rpoB gene. Each primer in the DPCR primer sets was assessed
for its specificity in a separate PCR reaction in the same con-
dition and an amplicon of either 235-bp fromMTB complex or
136-bp from NTM was observed. In total, 78 clinical strains
were analyzed by DPCR and 2 were identified as (136-bp for
NTM strains) M. avium (a non-mycobacteria), and all of the
remaining strains were phylogenetically MTB complex and
observed with 235-bp amplicon in agarose gel. Biochemical
and PCR procedures (Table 3) were found to have satisfactory
results to successfully identify and differentiate M. avium in
this clinical setting. In addition, the reference MTB H37Rv
ATCC 27294 and Mycobacterium smegmatis mc2155 ATCC
19420 strains were also included in this study to avoid incon-
sistency of the DPCR method. As expected, 235-bp product
was obtained for MTB H37Rv ATCC 27294 and 136-bp for M.
smegmatis mc2155 ATCC 19420. Therefore, the DPCR assay
can be used for the successful differential identification ofbiochemical and molecular procedures in clinical specimen.
Heat-stable catalase
test (@ 68 C)
PCR
IS6110 mtp40 DPCR
Inhibition +ve +ve 235-bp
No inhibition ve ve 136-bp
hain reaction; DPCR: Duplex polymerase chain reaction.
Fig. 1 – DRE-PCR assay examples. (a) Lane 1: M. tuberculosis H37Rv, lane 2–18: DRE-PCR amplified products banding pattern,
lane 9: 100-bp molecular marker. Variations were observed in the positions of the bands based on different MWs of the
amplified products. (b) An example of Category III clinical strains. For example, the commonly isolated category strain
designated C yields three bands. (c) Category of all sensitive strains isolated from different patients generated
indistinguishable patterns by the DRE-PCR method.
Fig. 2 – DPCR assay (Representative examples of MTB isolates). Lane 1: Marker DNA (100-bp ladder), lane 2: Positive control of
M. tuberculosis H37Rv ATCC 27294, lanes 3–8: Amplicon of size 235-bp was amplified from M. tuberculosis complex from
HIV-negative clinical isolates.
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the identification of NTM by DPCR, further confirmation was
carried out by RFLP analysis and by direct sequencing for
NTM species identification. Auspiciously, DPCR yielded only
one product at 235-bp for MTB strains, and 136-bp product
for M. avium strains from HIV-positive patients; no Mycobacte-
rium bovis or Mycobacterium africanum were identified in this
study setting irrespective of the clinical isolates tested. More-
over, the (235-bp) rpoB DNAs of MTB have confirmed that all
the isolates were phylogenetically related, and similar resultswere also obtained by conventional biochemical testing (nia-
cin production, PNB test and nitrate reductase reaction).
The lower sensitivity of the sputum smear microscopy not
only makes it difficult to identify NTM, it also makes it
difficult to implement the DOTS strategy in a clinical setting
[7]. To date, the impact of PCR technology in TB-control pro-
grams is unavoidable. Therefore, it is necessary to analyze
the mycobacterial species responsible for dissemination
within the hospitalized patients. In this study setting, it was
identified thatM. avium (2.56%) of NTM found in HIV-negative
Fig. 3 – DPCR assay examples of NTM isolates. Lane 1:
Marker DNA (100-bp ladder), lane 2: Positive control of M.
smegmatis mc2155 ATCC 19420, lanes 3 and 4: Amplicon of
size 136-bp was amplified from M. avium isolate from HIV-
positive patients.
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drugs and labeled as MDR-TB cases. Therefore, it is recom-
mended to exploit DPCR assay to identify and differentiate
the causative mycobacterial species from a clinical specimen
as an alternative to avoid over compliance with anti-TB drugs
and to avoid its side effects.
A local institutional-based epidemiology database has
been created to stratify the strains and prevalence of drug
resistance among the patients studied. The combined usage
of DRE and DPCR protocols introduced here resulted in the
amplification of bands and hence helps clinicians to deter-
mine and discriminate causative mycobacterial species to
avert further spread [23,24]. It is important to note that 68%
of the isolates from patients displayed drug resistance to at
least one drug. This greater difference could be partially
attributed to the smaller sample size of patients hospitalized
at Puducherry, South India; however, it did not change the
national average significantly.
In this study, the primers Tbc1, Tbc2 & M5, RM3 were
selected from the rpoB gene of MTB and NTM to differentiate
MTB from NTM. Pinsky and Banaei [9] developed a cost-effec-
tive, real-time PCR assay targeted to identify MTB complex
members; however, in most of the laboratories the implemen-
tation of real-time PCR remains difficult due to its cost and
standardization of protocol. Hence, the usage of conventional
PCR is still unavoidable in resource-poor settings, but it
should be instituted to meet the technological innovations
to increase its efficiency.
Conclusions
The usage of DRE-PCR and DPCR PCR of rpoB gene methods
possibly identify and differentiate the MTB complexes and
the M. avium species directly from clinical specimens in asingle reaction. In addition, DRE-PCR could be used as a
simple and rapid screening method to stratify a large number
of isolates into clusters and to create a database based on the
banding pattern of MTB isolates in agarose gel electrophore-
sis. This can help the physician to identify a range of
drug-resistant strains.
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